Inactive Instrument

Selectimmune Pharma AB (publ)

SELECT B

SE0012622785

Selectimmune Pharma AB Announces Resignation of Ann Gidner as CEO

March 27, 2022 at 09:21 am

SelectImmune Pharma AB's CEO Ann Gidner will leave SelectImmune Pharma, having accepted an offer from a non-competing Life-Science company. Ann Gidner will remain in the CEO role during the notice period of one month. The board has initiated the recruitment of a new CEO for the company.

Latest news about Selectimmune Pharma AB (publ)

Selectimmune Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	29/08/23	CI
Selectimmune Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	25/05/23	CI
Hamlet BioPharma AB (NGM:HAMLET B) completed the acquisition of Selectimmune Pharma AB.	16/05/23	CI
Hamlet Pharma AB (NGM:HAMLET B) agreed to acquire Selectimmune Pharma AB (NGM:SELECT B).	30/03/23	CI
Selectimmune Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23/02/23	CI
Selectimmune Pharma AB Elects Magnus Nylén as New Member of Board	24/11/22	CI
Selectimmune Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2022	16/11/22	CI
Selectimmune Pharma Has Successfully Completed Preparations to Start A Controlled Clinical Trial in Patients with Bladder Pain Syndrome	14/11/22	CI
Selectimmune Pharma AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2022	30/08/22	CI
Selectimmune Pharma AB Reports Earnings Results for the Full Year Ended June 30, 2022	30/08/22	CI
Selectimmune Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	24/05/22	CI
Selectimmune Pharma AB Appoints Gabriela Godaly as Acting CEO	26/04/22	CI
Selectimmune Pharma AB Receives Approval to Conduct A Placebo-Controlled Clinical Study of Bladder Pain	25/04/22	CI
Selectimmune Pharma AB to Conduct Clinical Trials in Cystitis and Bladder Pain Syndrome	29/03/22	CI
Selectimmune Pharma AB Announces Resignation of Ann Gidner as CEO	27/03/22	CI
Selectimmune Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	24/02/22	CI
SelectImmune Pharma AB Files Important Patent Application for Acute Pyelonephritis	01/02/22	CI
Selectimmune Pharma AB Reports Earnings Results for the First Quarter Ended September 30, 2021	18/11/21	CI
Selectimmune Pharma AB Publ Reports Earnings Results for the Fourth Quarter Ended June 30, 2021	31/08/21	CI
Start of the Selectimmune Pharma Phase II Trial of Targeted Immunotherapy in Recurrent Acute Cystitis	30/08/21	CI
SelectImmune Pharma Collaborates with Lonza to Develop an Immunotherapeutic Drug Candidate	21/06/21	CI
Selectimmune Pharma AB Publ Reports Earnings Results for the Third Quarter Ended March 31, 2021	25/05/21	CI
Selectimmune Pharma AB Publ Reports Earnings Results for the Second Quarter Ended December 31, 2020	26/02/21	CI
8,816,639 B Shares of Selectimmune Pharma AB are subject to a Lock-Up Agreement Ending on 27-OCT-2020.	26/10/20	CI
Selectimmune Pharma AB has completed an IPO in the amount of SEK 30 million.	25/06/19	CI

Chart Selectimmune Pharma AB (publ)

Duration

Period

More charts

Company Profile

Selectimmune Pharma AB is a Sweden-based pharmaceutical company. The Company develops new ways of equipping the host immune system to fight off the infections. The products are aimed at strengthening the immune system and are mainly used for the treatment of infectious diseases, as well as chronic inflammation. The Company is committed to exploring new medical innovations and solutions for the treatment of acute and chronic infections and their sequels. Selectimmune Pharma develops immunotherapies as alternatives to antibiotics.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+43.17%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.15%	242B
ROCHE HOLDING AG	+1.96%	224B
NOVARTIS AG	+13.36%	218B
AMGEN INC.	+8.48%	168B

Other Pharmaceuticals